Close
Nordic 9Nordic 9

Stassi Anastassov (investor - Angel Investor)

Sweden
See something wrong or missing? Let us know
Offices:Lausanne

Stassi Anastassov is a private investor living in Switzerland, former CEO at Duracell.

Average round investment:1.84M USD
Average number per year:1.0
Distribution: 2023 (1)2018 (1)
Portfolio companies: Sweden iCellate
Mostly invests in: Sweden Sweden (2) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Stassi Anastassov

Name Criteria
Sweden Albert & Anna Göranssons Minne
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Hans Frykman
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Johan Markman
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Thomas Feldthus
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Hong Kong MCG Technology Group
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden CBC Investment Group
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Good Growth Capital
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Poland Montis Capital
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Peppermint Venture Partners
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Rhia Ventures
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top